Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
* [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | * [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] | ||
| − | * [[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease | + | * [[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21 Streamlined Profile]] |
:* 32 pages including Conformance Checklists | :* 32 pages including Conformance Checklists | ||
| Line 27: | Line 27: | ||
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] | ||
| − | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification | + | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]] |
| − | *[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging | + | *[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging 2019-12-20]] |
| − | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility | + | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]] |
| − | *[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK | + | *[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]] |
| − | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease | + | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]] |
| − | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease | + | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]] |
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | *[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | ||
| − | *[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis | + | *[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2022-04-25]] ('''closed''' on May 3, 2022) |
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022) | :*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022) | ||
| Line 49: | Line 49: | ||
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form'''] | '''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form'''] | ||
| − | *[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE | + | *[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE Quantification 2020-10-12]] ('''closed''' on March 10, 2021) |
| − | *[[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK | + | *[[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK Cartilage for Joint Disease 2020-05-18]] ('''closed''' on October 29, 2020) |
| − | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017) | + | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017) |
Revision as of 19:31, 18 October 2022
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- 32 pages including Conformance Checklists
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklist, Appendix B) 2020-10-23
- US Shear Wave Speed for Liver Fibrosis 2022-04-25 (closed on May 3, 2022)
- Appendix E: SWS Checklists (updated April 25, 2022)
Stage 1: Public Comment Profiles
Please submit comments using the online form
- MR DCE Quantification 2020-10-12 (closed on March 10, 2021)
- MR MSK Cartilage for Joint Disease 2020-05-18 (closed on October 29, 2020)
- fMRI for Sensorimotor Mapping 2017-06-19 (closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)